(AIM: SAR)

14 Sept 2011

SAREUM HOLDINGS PLC
(“Sareum” or the “Company”)

 

Sareum to Present at European Cancer Cluster Partnering Conference

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, will make two presentations at the European Cancer Cluster Partnering Meeting (ECCP) conference, being held in Toulouse, France.

Today, Dr Mitchell will illustrate the ability of Chk1 inhibitors to increase the potency of chemo- and radio- therapy at the European Technology Showcase session. The presentation will highlight public data from Sareum’s recently announced Chk1 pre-clinical development candidate and other companies’ Chk1 inhibitors. Tomorrow, Dr Mitchell will update the conference on Sareum and its cancer research pipeline at a Company Presentations session.

Sareum’s CEO, Dr Tim Mitchell, commented: “This exciting conference offers us great opportunities to present Sareum and our cancer research programmes to representatives from international pharmaceutical and biotechnology companies.”

 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk